		Technical Data
029445	Citrulline

Description:
Citrulline is thought to be an unincorporated amino acid that plays a part in intermediary metabolism. It is produced in the small intestine by enterocytes. Citrulline concentration in plasma and serum is thought to be a reliable and noninvasive biomarker of small intestine function and mass during disease. Citrulline has also been shown to play an important role in protein homeostasis. Modified citrulline is a chemically modified form of citrulline that is more immunogenic.

Applications:
Suitable for use in ELISA, Dot Blot and Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000
Dot Blot: 1:125
Optimal dilutions to be determined by the researcher.

Positive Control:
Modified Tape-Stripped Cornified cells

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Type	Isotype	Clone	Grade
Pab			Affinity Purified

Size		Storage	Shipping	Source	Host
100ul		-20°C	Blue Ice	Human	Rabbit

Concentration:

As reported

Immunogen:

Modified de-iminated calf thymus core Histones.

Purity:

Purified by immunoaffinity chromatography.

Form

Supplied as a liquid in PBS, 0.05% sodium azide.

Specificity:

Recognizes any proteins containing modified citulline, hence various molecular weight bands can be expected.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1. Oliverius, M., et al. (2010). Cas Lek Cesk. 149(4):160-162. 2. Crenn, P., et al. (2008). Clin Nutr. 27(3):328- 339. 3. Curis, E., et al. (2007). Curr Opin Clin Nutr Metab Care. 10(5):620-626. 4. Moinard, C., et al. (2007). J Nutr. 137(6 Suppl 2):1621S-1625S. 5. Senshu, T., et al. (1995). J Invest Dermatol. 105:163-169. 6. Senshu, T., et al. (1992). Anal Biochem. 203:94-100. 7. Hagiwara, T., et al. (2002). Biochem Biophys Res Commun. 290:979-983. 8. Masson-Bessiere, C., et al. (2001). J Immunol. 166:4177-4184. 9. Ishida-Yamamoto, A., et al. (2000). J Invest Dermatol. 114:701-705.